The Bizarre Assessment of Biotech Firms in the Stock Market
The Clinical-Stage Biotechnology Firms
We are witnessing inexplicable evaluations of clinical-stage biotechnology companies. Bizarre is the best description of this group’s assessment which is based on incomes that do not exist in biotech firms that are yet to have approved and marketed products anywhere in the world.
Unfortunately, the most impacted firms by the bizarre evaluation in this sector are biotech firms with solid fundamentals which include; solid science, breakthrough technologies and promising investigational products. The clinical-stage firms we selected have demonstrated encouraging early and mid . . .